MedPath

Testing Spectrosense EVA System for Detection of Breast Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air

Conditions
Breast Cancer
Registration Number
NCT01849328
Lead Sponsor
Rauscher, Gregory E., M.D. PA
Brief Summary

Volatile Organic Compounds (VOC) in human breath are captured and analyzed by the Spectrosense EVA system, which is combination of a gas chromatography (GC) and software algorithm. The objective is to obtain a set or sets of VOC bio-markers that will provide the best discrimination between Breast Cancer sick population and healthy population. The gold standard for identifying sick/healthy population is biopsy proven breast cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
600
Inclusion Criteria
  • Age from 18 years old
  • Breast cancer positive biopsy
  • Before any treatment
  • Signed Informed Patient Consent
Exclusion Criteria
  • Age under 18 years old
  • Neoadjovant treatment
  • Post surgery for breast cancer
  • A history of any other cancer type, except skin cancer that is not melanoma

Healthy group:

Inclusion Criteria:

  • Healthy women
  • No history of Breast cancer
  • Signed Informed Patient Consent

Exclusion Criteria:

  • History of Breast cancer
  • Breast cancer background in the family
  • A history of any other cancer type, except skin cancer that is not melanoma

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Obtaining a set or sets of VOC bio-markers that will provide the best discrimination between Breast Cancer sick population and healthy population. breast cancer.Upon enrollment.
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Englewood Hospital and Medical Center

🇺🇸

Englewood, New Jersey, United States

© Copyright 2025. All Rights Reserved by MedPath